Health Care [ 11/12 ] | Biotechnology [ 67/74 ]
NASDAQ | Common Stock
Acurx Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, develops antibiotics to treat bacterial infections in the United States.
The company's lead antibiotic candidate is ibezapolstat, a novel mechanism of action that targets the polymerase IIIC enzyme that is in Phase 2b clinical trial to treat patients with clostridium difficile infections.
It also develops ACX-375C, a potential oral and parenteral treatment targeting gram-positive bacteria, including methicillin-resistant staphylococcus aureus, vancomycin-resistant enterococcus, and penicillin-resistant streptococcus pneumonia; and CCP, multiple product candidates for gram-positive infections.
Acurx Pharmaceuticals, Inc. was incorporated in 2017 and is headquartered in Staten Island, New York.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Mar 17, 25 | -0.16 Increased by +56.76% | -0.18 Increased by +11.11% |
| Nov 13, 24 | -0.17 Increased by +29.17% | -0.20 Increased by +15.00% |
| Aug 8, 24 | -0.26 Increased by +7.14% | -0.22 Decreased by -18.18% |
| May 14, 24 | -0.28 Decreased by -12.00% | -0.24 Decreased by -16.67% |
| Mar 15, 24 | -0.37 Decreased by -32.14% | -0.26 Decreased by -42.31% |
| Nov 13, 23 | -0.24 Increased by +25.00% | -0.27 Increased by +11.11% |
| Aug 11, 23 | -0.28 Decreased by -7.69% | -0.27 Decreased by -3.70% |
| May 12, 23 | -0.25 Increased by +3.85% | -0.29 Increased by +13.79% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Dec 31, 24 | 0.00 Decreased by N/A% | -2.78 M Increased by +45.61% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 24 | 0.00 Decreased by N/A% | -2.82 B Decreased by -90.48 K% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 24 | 0.00 Decreased by N/A% | -4.12 M Decreased by -19.64% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 24 | 0.00 Decreased by N/A% | -4.38 M Decreased by -50.81% | Decreased by N/A% Decreased by N/A% |
| Dec 31, 23 | 0.00 Decreased by N/A% | -5.11 M Decreased by -351.78% | Decreased by N/A% Decreased by N/A% |
| Sep 30, 23 | 0.00 Decreased by N/A% | -3.11 M Increased by +12.05% | Decreased by N/A% Decreased by N/A% |
| Jun 30, 23 | 0.00 Decreased by N/A% | -3.45 M Decreased by -31.47% | Decreased by N/A% Decreased by N/A% |
| Mar 31, 23 | 0.00 Decreased by N/A% | -2.90 M Decreased by -8.72% | Decreased by N/A% Decreased by N/A% |